Equities

Castle Biosciences Inc

CSTL:NMQ

Castle Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)33.29
  • Today's Change-0.02 / -0.06%
  • Shares traded396.27k
  • 1 Year change+85.36%
  • Beta0.9471
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments243259330
Total Receivables, Net382317
Total Inventory7.943.982.02
Prepaid expenses6.296.214.81
Other current assets, total------
Total current assets296292354
Property, plant & equipment, net382617
Goodwill, net1111--
Intangibles, net10711689
Long term investments------
Note receivable - long term1.191.091.31
Other long term assets1.441.111.72
Total assets453447463
LIABILITIES
Accounts payable104.732.55
Accrued expenses342921
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.070.150.11
Other current liabilities, total3.481.821.66
Total current liabilities483625
Total long term debt0.030.090.12
Total debt0.100.240.23
Deferred income tax0.210.430.64
Minority interest------
Other liabilities, total141225
Total liabilities624851
SHAREHOLDERS EQUITY
Common stock0.030.030.03
Additional paid-in capital609560505
Retained earnings (accumulated deficit)(218)(161)(94)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.14(0.38)--
Total equity391399412
Total liabilities & shareholders' equity453447463
Total common shares outstanding272725
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.